[
  {
    "ts": "2026-01-05T08:30:00+00:00",
    "headline": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
    "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
    "url": "https://finance.yahoo.com/news/sterility-testing-market-reach-us-083000138.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "98cccf96-7333-3e8c-b8bd-208a47d161a3",
      "content": {
        "id": "98cccf96-7333-3e8c-b8bd-208a47d161a3",
        "contentType": "STORY",
        "title": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
        "description": "",
        "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
        "pubDate": "2026-01-05T08:30:00Z",
        "displayTime": "2026-01-05T08:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sterility-testing-market-reach-us-083000138.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sterility-testing-market-reach-us-083000138.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T12:36:16+00:00",
    "headline": "Novo Nordisk launches Wegovy pill to US self-pay patients",
    "summary": "<body><p>STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).</p><p>The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.</p><p>The U.S. Food and Drug Administration approved the pill last month.</p><p>It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.</p><p>It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.</p><p>The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.</p><p>The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.</p><p>The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.</p><p>A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.</p><p>That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.</p><p>Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisk-launches-wegovy-pill-123616915.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "fc0bbc56-973d-333a-b9cf-810e9b1285ca",
      "content": {
        "id": "fc0bbc56-973d-333a-b9cf-810e9b1285ca",
        "contentType": "VIDEO",
        "title": "Novo Nordisk launches Wegovy pill to US self-pay patients",
        "description": "<title><body><p>STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).</p><p>The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.</p><p>The U.S. Food and Drug Administration approved the pill last month.</p><p>It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.</p><p>It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.</p><p>The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.</p><p>The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.</p><p>The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.</p><p>A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.</p><p>That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.</p><p>Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.</p></body></title>",
        "summary": "<body><p>STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).</p><p>The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.</p><p>The U.S. Food and Drug Administration approved the pill last month.</p><p>It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.</p><p>It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.</p><p>The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.</p><p>The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.</p><p>The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.</p><p>A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.</p><p>That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.</p><p>Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.</p></body>",
        "pubDate": "2026-01-05T12:36:16Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/7kud2n44OQsghjsvGLr6NQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a7e77e-d45c-4462-a54d-56ee57086c2a/main/1280x720/39s137ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M8gntrwIVIGLOkAzSl5jJA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a7e77e-d45c-4462-a54d-56ee57086c2a/main/1280x720/39s137ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YH2_lNheVM1qzQ6H4ain1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a7e77e-d45c-4462-a54d-56ee57086c2a/main/1280x720/39s137ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-launches-wegovy-pill-123616915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-launches-wegovy-pill-123616915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T12:07:46+00:00",
    "headline": "Novo Nordisk to Sell Wegovy Pill in U.S. Starting at $149 per Month",
    "summary": "Launch targets self-pay market as company expands weight-loss portfolio",
    "url": "https://finance.yahoo.com/news/novo-nordisk-sell-wegovy-pill-120746635.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "c9929530-3890-32be-9353-ef168808b1ef",
      "content": {
        "id": "c9929530-3890-32be-9353-ef168808b1ef",
        "contentType": "STORY",
        "title": "Novo Nordisk to Sell Wegovy Pill in U.S. Starting at $149 per Month",
        "description": "",
        "summary": "Launch targets self-pay market as company expands weight-loss portfolio",
        "pubDate": "2026-01-05T12:07:46Z",
        "displayTime": "2026-01-05T12:07:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sell-wegovy-pill-120746635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-sell-wegovy-pill-120746635.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T04:37:57+00:00",
    "headline": "2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finance.yahoo.com/news/2-unpopular-stocks-deserve-love-043757295.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "cd3cfe07-6dc7-3857-b046-3b005c716dac",
      "content": {
        "id": "cd3cfe07-6dc7-3857-b046-3b005c716dac",
        "contentType": "STORY",
        "title": "2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm",
        "description": "",
        "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
        "pubDate": "2026-01-05T04:37:57Z",
        "displayTime": "2026-01-05T04:37:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/19d976841a7cf02344c7d4020c2f5a5c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ANF Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jv6f8b0C5xrtanropNdkQQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/19d976841a7cf02344c7d4020c2f5a5c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/17S3F0SpkuMnwoYVpYgIWg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/19d976841a7cf02344c7d4020c2f5a5c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-unpopular-stocks-deserve-love-043757295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-unpopular-stocks-deserve-love-043757295.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ANF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DIN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]